Anavex to commence Phase II trial of schizophrenia drug candidate

The unique mechanism of action of ANAVEX 3-71 is believed to offer a comprehensive treatment option for all symptom domains of schizophrenia, positive, negative, and cognitive while also alleviating the side effects associated with standard antipsychotic medications.

4 Likes